BBOT at a glance
BridgeBio Oncology Therapeutics Inc (BBOT, SEC CIK 1869105) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 8, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Oncology Therapeutics Inc (BBOT) reported revenue of $11.3 million (up 77.9% from FY2024) and a net loss of $134.0 million. Diluted EPS was -$4.30.
- As of June 30, 2026, 16 institutional investment managers tracked by SignalX reported holding BridgeBio Oncology Therapeutics Inc (BBOT) shares worth $89.6 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $11.3M
- +77.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 16 funds
- $89.6M · +3 vs prior quarter
- Latest 10-Q
- Aug 11, 2026
- Quarterly report
SignalX for BBOT
Don't miss the next BBOT filing
- Alerts as it files. A push when BBOT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BBOT, by share count.
- Ask anything. An AI agent that reads every BBOT filing and answers with sources.
BBOT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cobo Marc | F | Oct 1, 2026 | 126 | $3.94 |
| Elmelech Idan | F | Oct 1, 2026 | 343 | $3.94 |
| Ben Yong | F | Oct 1, 2026 | 1,047 | $3.94 |
| Beltran Pedro | F | Oct 1, 2026 | 1,047 | $3.94 |
| Cobo Marc | F | Sep 10, 2026 | 203 | $5.52 |
| Cobo Marc | A | Sep 10, 2026 | 9,038 | - |
| Cobo Marc | A | Sep 10, 2026 | 43,700 | - |
| Chen Bihua | J | Jul 1, 2026 | 1,704,862 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $6.4M | $11.3M |
| Operating Income | -$42K | -$584K | -$145.8M |
| Net Income | -$42K | $7.6M | -$134.0M |
| Op. Margin | - | -9.2% | -1285.5% |
| Net Margin | - | 119.2% | -1181.7% |
| Balance Sheet | |||
| Total Assets | $333K | $194.4M | $448.4M |
| Equity | -$64K | -$3.7M | $411.1M |
| ROE | 65.6% | -203.6% | -32.6% |
| Per Share | |||
| EPS | - | $-5756.41 | $-4.30 |
| Cash Flow | |||
| Operating CF | - | -$764K | -$113.9M |
| CapEx | - | $49K | $606K |
Source: XBRL data in BridgeBio Oncology Therapeutics Inc (BBOT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BBOT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 16 | $89.6M |
| Q1 2026 | 13 | $85.6M |
| Q4 2025 | 14 | $124.9M |
| Q3 2025 | 11 | $112.7M |
- Vanguard Capital Management LLC+1.47M (+272%)
- State Street Corp+810.3K (+358%)
- Citadel Advisors LLC+89.1K (+4%)
- Northern Trust+84.2K (+82%)
- BlackRock+65.7K (+3%)
- Millennium Management−160.5K (-60%)
- T. Rowe Price Group−137.9K (-31%)
- Goldman Sachs Group−65.5K (-39%)
- Renaissance Technologies LLC−43.3K (-42%)
- Morgan Stanley−40.0K (-92%)
- Bank of America Corp+77.1K
- Two Sigma Investments+26.5K
- Citigroup+19.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 54 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BBOT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BBOT SEC filings: frequently asked questions
Which institutions hold BBOT stock?
As of June 30, 2026, the largest BridgeBio Oncology Therapeutics Inc (BBOT) holders among the 13F filers tracked by SignalX were Alphabet Inc ($21.5 million), Citadel Advisors LLC ($19.9 million), BlackRock ($16.4 million), Vanguard Capital Management LLC ($15.3 million), State Street Corp ($7.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BBOT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Oncology Therapeutics Inc (BBOT) reported revenue of $11.3 million (up 77.9% from FY2024) and a net loss of $134.0 million. Diluted EPS was -$4.30. The figures come from the XBRL data in the 10-K.
What are the latest BBOT SEC filings?
BridgeBio Oncology Therapeutics Inc (BBOT) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 8, 2026 and a Form 4 insider filing on October 5, 2026.
What is BBOT's SEC CIK number?
BridgeBio Oncology Therapeutics Inc (BBOT)'s SEC Central Index Key (CIK) is 1869105. EDGAR lists every BBOT filing under that number.
Ask anything about BBOT
The research agent reads BBOT's filings, financials, insider trades and 13F holders, then answers with sources.